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Background: In Guinea Elapids are responsible for 20% of envenomations. The associated case fatality rate (CFR)
ranged 15-27%, irrespective of treatment.
Results: We studied 77 neurotoxic envenomations divided in 3 groups: a set of patients that received only
traditional or symptomatic treatments, and two other groups that received either 2 or 4 initial vials of AntivipmynW
Africa renewed as necessary. CFR was 27.3%, 15.4% and 17.6%, respectively. Although antivenom treatment was
likely to reduce CFR, it didn’t seem to have an obvious clinical benefit for the patients, suggesting a low treatment
efficacy. Mean delay to treatment or clinical stages were not significantly different between the patients who
recovered and the patients who died, or between groups. Interpretation of these results is complicated by the lack
of systematic studies under comparable conditions. Of particular importance is the absence of assisted ventilation,
available to patients in all the other clinical studies of neurotoxic envenomation.
Conclusion: The apparent lack of clinical benefit may have several causes. The hypothesis of a limited therapeutic
window, i.e. an insufficient formation of antigen-antibody complexes once toxins are bound to their targets and/or
distributed beyond the reach of antivenom, should be explored.
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The efficacy of immunotherapy and its role in the
treatment of envenomation are well established and
not in question, at least in Africa [1,2]. The limited
availability of antivenoms has led several manufacturers
from emergent countries to propose their services to
alleviate this critical deficit [3-6]. Two clinical studies
conducted in northern Cameroon in 1993 and 1996
established the safety of F(ab’)2-based antivenoms ad-
ministered by perfusion or direct intravenous injection
[7,8]. Between 2005 and 2006, a clinical study using
AntivipmynW Africa, with results judged to be very suc-
cessful, was conducted in Benin [9]. However, these clinical
studies were concerned essentially with envenomations
caused by Viperidae, particularly Echis ocellatus, a species* Correspondence: jean-philippe.chippaux@ird.fr
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reproduction in any medium, provided the orlargely predominant in the savannas of West Africa. A
clinical study in Guinea confirmed the apparent general
efficacy and safety of AntivipmynW Africa [10]. However,
it revealed shortcomings regarding the treatment of
envenomations by Elapidae.
We have reexamined the available records in Upper
and Lower Guinea (Figure 1) to evaluate the efficacy and
shortcomings of immunotherapy relative to the absence
of specific treatment in patients with overt neurological
symptoms due to envenomation by African Elapidae.
Patients were divided into three groups according to
treatment protocol.
Methods
An initial group of 33 patients was retrospectively
composed after assemblage of clinical information from
hospitalization registries of a health center in the region
of Kankan (Upper Guinea). None of them had received
antivenom as it was unavailable at that time. Two other
groups were based on prospective clinical studies at thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Location of survey sites in Guinea.
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order to ascertain the safety and efficacy of AntivipmynW
Africa under real field conditions, the results of which
have been published elsewhere [10]. The second group
included 26 patients who were treated during the years
2009 and 2010. Patients received an initial dose of 2
vials of antivenom renewed as a function of clinical
evolution 3, 6, 12 and 24 hours after the first dose
(low-dose group). Since the results appeared unsatis-
factory, the design of the study was amended in 2011
to increase the dose of antivenom accordingly. The
third group included 18 patients (but only 17 treated
because one died on arrival before treatment). They
received twice the initial dose (4 vials), renewed as a
function of evolution 3, 6, 12 and 24 hours after the
initial dose (high-dose group).Table 1 Gradation of neurological symptoms
Score Symptoms
Grade 1 Local paraesthesia (anesthesia, tingling, stinging)
Grade 2 Hypersecretion (sweat, saliva)
Grade 3 Impaired vision, hearing, speech, dysphagia
Grade 4 Bilateral ptosis
Grade 5 Severe dyspnea
Grade 6 Severe consciousness disorders, motor and
respiratory paralysisWe included all bitten patients who had presented
neurological disorders: local paresthesia, tremors and
muscular contractions, palpebral ptosis, vision impair-
ment, tinnitus, dysarthria, consciousness disorders,
dyspnea, hypersecretion. The severity and surveillanceFigure 2 Flow chart of inclusion and outcome of patients from
Upper and Lower Guinea.
Table 2 Symptoms and time to death in patients of group 1
N Time of the bite Sex and age Treatment Symptoms at presentation Time of the death Time between
bite and death
1 8:10 a.m. M – 15 Traditional Hypersalivation; blurred vision 10:45 a.m. 2:35
2 9:00 p.m. M – 43 Symptomatic Breathlessness 4:00 a.m. 7:00
3 3:20 p.m. F – 56 Traditional and symptomatic Weakness; sweat 11:10 p.m. 7:50
4 11:00 a.m. M – 23 Symptomatic Ptosis 7:00 p.m. 8:00
5 0:50 p.m. M – 17 Traditional Blurred vision 2:15 p.m. 1:25
6 4:20 p.m. F – 32 Traditional and symptomatic Consciousness disorders 1:00 p.m. 20:40
7 8:00 p.m. F – 8 Symptomatic Blurred vision and consciousness disorders 12:30 a.m. 16:30
8 5:00 p.m. F – 36 Traditional Hypersalivation, consciousness disorders 4:10 a.m. 11:10
9 2:30 p.m. M – 51 Traditional and symptomatic Local bleeding; breathlessness Day 2: 6:00 p.m. 27:30
Table 3 Symptoms and time to death in patients of group 2 (low dose of antivenom)




Snake species Vials of
antivenom
Associated symptoms Outcome
8 3 4 D. viridis 2 Recovery H6
16 21 5 D. viridis 4 Recovery H6
17 11 3 1 Recovery H6
19 18 6 D. polylepis 4 Edema Death H7
20 48 2 1 Recovery H3
26 5 5 D. viridis 4 Recovery H6
27 6 6 4 Local bleeding Recovery H6
29 2 6 2 Local bleeding Death H1
33 47 2 1 Recovery H3
37 2 1 2 Recovery H3
38 13 3 1 Edema Recovery H3
53 15 1 1 Local bleeding and edema Recovery H3
59 4 4 2 Bleeding Recovery H3
71 10 4 4 Edema Recovery H6
77 20 3 D. viridis 2 Edema Recovery H3
87 7 5 D. viridis 6 Recovery H48
88 4 5 4 Recovery H24
119 3 5 D. viridis 2 Recovery H24
123 3 4 1 Recovery H6
124 10 5 2 Recovery H24
130 3 1 2 Local bleeding Recovery H6
134 14 3 Naja sp. 4 Edema Death H4
138 4 2 3 Recovery H6
141 2 2 D. polylepis 6 Death H7
148 6 4 Naja sp. 2 Edema Recovery H12
149 1 2 N. melanoleuca 1 Local bleeding Recovery H6
H: hour after initial antivenom dose.
Baldé et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2013, 19:6 Page 3 of 8
http://www.jvat.org/content/19/1/6
Table 4 Symptoms and time to death in patients of group 3 (high dose of antivenom); one death (#11) was not
recorded because the patient died before treatment, less than three hours after the bite









1 2 2 4 Death H2
2 7 4 D. viridis 4 Edema Recovery H3
3 7 4 Naja sp. 4 Edema Recovery H7
4 2 1 4 Recovery H5
5 3 2 Naja sp. 4 Recovery H5
6 3 5 D. polylepis 4 Local bleeding Death H1
7 1 1 N. nigricollis 4 Edema Recovery H4
8 2 4 4 Local bleeding Death H2
9 4 1 4 Local bleeding Recovery H2
10 1 2 4 Recovery H4
12 4 4 Naja sp. 4 Edema Recovery H5
13 4 1 4 Recovery H2
14 5 6 4 Edema Recovery H2
15 6 4 D. viridis 4 Recovery H3
16 5 3 4 Recovery H5
17 10 6 6 Recovery H3
18 18 2 4 Recovery H6
H: hour after initial antivenom dose.
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(Table 1) [10].
AntivipmynW Africa, manufactured by Bioclon Institute
(Mexico), is composed of highly purified lyophilized F
(ab’)2 immunoglobulin fragments [11]. It is produced
by immunization of horses with the venoms of Bitis
gabonica, B. arietans, Echis ocellatus, E. leucogaster, E.
pyramidum, Naje haje, N. melanoleuca, N. nigricollis,
N. pallida, Dendroaspis viridis and D. polylepis. Preclinical
testing indicated a specific neutralizing potency of more
than 250 LD50 per vial against all relevant species [11].
Administration of the antivenom was always by directTable 5 Comparison of score and time to death in the 3 groups
Group 1 Group 2 Group 3
(no antivenom) (low dose) (high dose)
Number of cases 33 26 17
Score at presentation Cured patients = ? Cured patients = 4 [2–5] Cured patients = 2.5 [1.3-4
Median [Q:0.25-0.75] Fatalities = 5 [3–6]* Fatalities = 4.5 [2.8-6] Fatalities = 4 [3–4.5]
Mean of antivenom ± SD [95%CI] 0 26.2 ± 5.9 mL 41.2 ± 2.3 mL
Number of fatalities 9 (27.3%) 4 (15.4%) 3 (17.6%)
Time to presentation – Cured patients = 5 [3.3-9.3] Cured patients = 3 [3.3-10
Median [Q: 0.25-0.75] Fatalities = 2.5 [2–6.8] Fatalities = 2 [2–8]
Time to death 8 [7–13.5] 5.5 [3.3-7] 4 [4–4]
Median [Q:0.25-0.75]













6intravenous push as detailed elsewhere and modified as
indicated in the Results section [9].
Statistical analysis used Wilcoxon rank sum test for time
to presentation, score and time to death, and Student’s
t test for treatment doses, with p = 0.05.Results and discussion
In the region of Upper Guinea, we analyzed 226 records
of patients bitten between 2005 and 2006. At the Pasteur
Institute of Guinea, in Lower Guinea, 521 patients were
treated from 2009 to 2011.]
]
Baldé et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2013, 19:6 Page 5 of 8
http://www.jvat.org/content/19/1/6The data collected as well as the outcomes are
summarized in Figure 2 and Tables 2, 3, 4, 5. There were
no significant differences either in the neurological scores
on arrival or in the delay of treatment between the three
groups. Administration of antivenom, independently
of dose, did not significantly reduce CFR between the
untreated group from Upper Guinea and either group
treated in Lower Guinea.
Data collection varied among the three groups due to
the conditions of the surveys and the treatment protocols.
The study in Upper Guinea was retrospective, a fact that
restricted the available information. In the two groups from
Lower Guinea, the treatment protocol changed due to
the apparently low efficacy of the AntivipmynW Africa
antivenom, as well as the modalities of patient surveil-
lance and the recovery criteria, which introduced some
intergroup heterogeneity. Some comparisons could not be
made among all groups, such as the delay in receiving
a consultation (this variable was not available for the
untreated group) or the time between bite and recovery in
surviving patients (since none of the groups followed the
same recovery criteria). In addition, Elapid species differ
slightly in these two aspects (Table 6). In the end, the only
parameters usable for comparison were the score on
arrival, the dose of antivenom, case fatality rate and the
time elapsed between bite and death (Table 6). As a
consequence, comparability between groups, as well as
patient series described in the literature, is limited. It
appears, however, that treatment failures are common even
when employing high doses of antivenom associated with
intensive symptomatic treatment (mechanical ventilation,
prostigmine etc.).
Our analysis of the records from the two health
centers allowed us to identify 77 patients who, on arrival,
presented neurological troubles strongly suggestive of
envenomation by Elapidae. In some cases species could
be identified either by examination of the specimen or







Naja nigricollis Common Common Local necrosis,
neurotoxic signs
Naja katiensis Common Absent Neurotoxic signs,
local necrosis
Naja melanoleuca Common Common Neurotoxic signs
Dendroaspis viridis Present Common Neurotoxic signs,
muscarinic syndrome
Dendroaspis polylepis Present Present Neurotoxic signs,
muscarinic syndrome
Pseudohaje nigra Absent Rare No envenomation
recordedpermitted, with a little experience, educated guesses of the
species or at least genera responsible for the envenomation
(Table 6). Some species of Naja are responsible for an
isolated neurological syndrome (syndrome cobraïque)
(Figure 3), or associated with local necrosis in the case
of envenomations by Naja nigricollis and N. katiensis
(both spitting cobras). Dendroaspis (in Guinea, D. viridis
and D. polylepis) envenomation is also associated with
the syndrome, a muscarinic symptomatology manifested
by abundant sweat, sialorrhea, vomit, diarrhea and my-
driasis [12] (Figure 4). We do not have information on
envenomations by Pseudohaje nigra.
A delay until consultation, which is detailed only for
patients in groups 2 and 3, appears to be a decisive factor
insofar as it delays treatment, which is more effective the
earlier it is administered [13-15]. The lack of significance
between the groups could result from the small number
of patients. Paradoxically, the delay in consultation is
longer (although not significantly) in patients who recov-
ered in comparison to those who died (Table 5). However,
some severely envenomed patient could have died before
reaching the health center. But there is no evidence to
support this hypothesis. In addition, the time between
bite and fatality in group 3 is remarkably shorter and
significantly different from that of the other two groups.
The duration of hospitalization is also much shorter,
which suggests either that envenomations were more
severe (even if scores on arrival were similar) or that shorter
delays were declared.
The efficacy of AntivipmynW Africa in these cases is
therefore directly questioned. There is no reason to
doubt its experimental neutralization capacity, but these
results do not seem to be transposed to the clinical
situation [11]. Dosage does not seem to be the issue, as
the same results are apparent at lower and higher
doses. In our study, doubling the initial dose did not
lead to a difference in the maximal dose administeredFigure 3 Neurotoxic syndrome due to Naja melanoleuca bite
(note pathognomonic ptosis) Photo by E. Stahel.
Figure 4 Associated neurotoxic and muscarinic syndromes due
to Dendroaspis sp bite (note hypersalivation and profuse
sweating) Photo by C. Baldé.











Guinea 26 25 ml 4 (15%) No Group 2
this study
[10–60]
Guinea 17 40 mL 3 (18%) No Group 3
this study
[40–60]
India 28 150 mL 0 VS [16]
India 27 600 mL 3 (11%) VS [16]
[300–1.600]
Sri Lanka 87 > 100 mL 5 (6%) VS [17]
[100–200]
Sri Lanka 25 100 mL 2 (8%)§ VS [18]
[80–200]
India 37 150 mL 11 (22%)* VS; AC [19]




139 50 mL 6 (4.3%) VS [13]
Papua New
Guinea
31 25 mL 0 VS; AC [13]
India 14 60 mL 1 (7%) VS [21]
India 12 120 mL 0 VS [21]
Thailand 68 100 mL 0 VS [22]




156 50 mL 3 (1.9%) VS [14]
Vietnam 42 50 mL 0 VS [24]
[50–100]
Thailand 85 40 mL 1 (1%) VS [25]
[10–200]
VS: ventilatory support; AC: anticholinesterase; §the patients died from
extensive necrosis; *three patients died before treatment.
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criteria for re-administration of antivenom were not
apparent during the monitoring of the patients. But
despite demonstrable neutralization in the animal
model, it is possible that the venom of a particular species
(of a total of four possible ones in Lower Guinea) is poorly
neutralized by the antivenom in humans; given the small
sample of patients and the lack of unambiguous snake
identification in most of them, this could skew the overall
results and mask some measure of overall efficacy. It is
also possible that the therapeutic window is simply very
narrow for some or all venoms.
More generally in Elapid envenomations, such low
apparent clinical efficacy has also been observed by
numerous authors who have obtained similar results,
even at much higher doses (Table 7). Furthermore, in
all other studies, antivenom use was associated with
mechanical ventilation on demand, as well as other
symptomatic treatments such as cholinesterase inhibi-
tors. These were not available for patients in the
present study. Although the species, and therefore
the toxicity and mode of action of their venoms, are
different, and the antivenoms – whose neutralizing
capacities are also variable – are not the same, it is
important to note that the treatment of Elapidae
envenomations is less effective than treatment of those
inflicted by Viperidae. In fact, the doses reported by
numerous authors (surpassing occasionally even a hundred
vials, a tendency which confirms a low level of efficacy)
seem unreasonable, with regard to both the quantity
of heterologous protein administered and the cost of
treatment, already prohibitive for extremely poor patients
even at much lower doses.
In hemorrhagic envenomations in the West African
savanna, a rapid arrest of hemorrhage and coagulopathy
was apparent after antivenom administration, requiring no
additional care to remove most patients from immediatedanger of life-threatening hemorrhage [7-9]. The lack
of therapeutic response in neurotoxic envenomations,
however, suggests that antivenom alone may not suf-
fice to ensure a sufficiently rapid recovery to prevent
respiratory failure and death. Under the extremely pre-
carious conditions of this study, potential benefits of
antivenom administration, such as a speedier recovery
from respiratory paralysis, would be masked by the
unavailability of assisted ventilation.
One possibility is that the antivenom has a low efficacy
after neurotoxins are fixed on the neuromuscular receptors,
which usually happens in the first few hours after the
bite [26]. In this view, the problem is immunochemical:
those epitopes recognized by the antibodies would be
masked on receptor-bound toxins and this would in turn
Baldé et al. Journal of Venomous Animals and Toxins including Tropical Diseases 2013, 19:6 Page 7 of 8
http://www.jvat.org/content/19/1/6prevent toxin-antibody complex formation, neutralization
and elimination.
A second hypothesis that merits attention is pharma-
cokinetic: the toxin-antibody encounter does not occur
because the antigen and the antibody are not found in
the same biological compartment. The antivenom is
largely present in the vascular compartment [27]. It is in
this compartment that antigen-antibody complex formation
occurs, provided that the relevant venom components are
there as well. It has been clearly shown that Viperidae
venoms are found in the blood, where they are bound
by antivenom [28]. To the best of our knowledge, it
has never been shown that neurotoxins from Elapidae
venoms were present in high proportion in the vascular
compartment, nor that neurotoxins are bound by F(ab')2
after intravenous administration.
Conclusion
During a clinical study in Guinea under true field con-
ditions, the administration of purified immunoglobulin
fragments to treat neurotoxic enevenomation due to
Elapidae has proven a disappointment, in agreement
with the results of numerous other clinical studies.
The hypothesis of insufficient venom neutralization is
difficult to maintain because, on one hand, the experimen-
tal neutralization of venoms is generally acceptable and, on
the other hand, this divergence has been noted for many
elapid venoms and antivenoms throughout the world.
Alternatively, a hypothesis of an absence of toxin-antibody
complex formation merits consideration; it could come
about by epitope masking on receptor-bound toxins and/or
by a failure of the antibodies to encounter the relevant
toxins due to pharmacokinetic constraints. In the first case,
the only recourse would be very early administration of
antivenom or the development of neutralizing antibodies
against epitopes not masked on receptor-bound toxins. In
the second case, another route of antivenom administration
should be considered.
In the meantime, it is advisable to administer antivenom
as early as possible after the bite to attempt to eliminate
available venom antigens and to secure assisted ventilation
in case the patient presents the onset of respiratory distress.
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